Back
MasTec, Inc. 10K Form
Buy
75
MTZ
MasTec, Inc.
Last Price:
$218.99
Seasonality Move:
8.85%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
| 2024-05-02 | 10Q | MTZ/MasTec, Inc. Quarterly |
| 2023-11-02 | 10Q | MTZ/MasTec, Inc. Quarterly |
| 2023-08-03 | 10Q | MTZ/MasTec, Inc. Quarterly |
| 2023-05-04 | 10Q | MTZ/MasTec, Inc. Quarterly |
| 2022-11-03 | 10Q | MTZ/MasTec, Inc. Quarterly |
| 2022-08-04 | 10Q | MTZ/MasTec, Inc. Quarterly |
Receive MTZ News And Ratings
See the #1 stock for the next 7 days that we like better than MTZ
MTZ Financial Statistics
Sales & Book Value
| Annual Sales: | $12.3B |
|---|---|
| Cash Flow: | $20.3M |
| Price / Cash Flow: | 41.46 |
| Annual Sales: | $39.45 |
| Price / Book: | 5.55 |
Profitability
| EPS (TTM): | 4.20580 |
|---|---|
| Net Income (TTM): | $353.7M |
| Gross Margin: | $1.1B |
| Return on Equity: | 11.82% |
| Return on Assets: | 3.85% |
MasTec, Inc. Earnings Forecast
Key MasTec, Inc. Financial Ratios
-
The Gross Profit Margin over the past 45 years for MTZ is 9.11%.
-
The Selling, General & Administrative Expenses for MTZ have been equal to 5.56% of Gross Profit Margin.
-
The Research & Development expenses have been 0.00% of Revenue.
-
The Interest Expense is 96.91% of Operating Income.
-
The Net Earning history of MTZ is 1.62% of Total Revenues.
-
Per Share Earnings over the last 45 years have been positive in 19 years.
MasTec, Inc. Stock Price Chart
Industry, Sector and Symbol
| Stock Exchange: | NYSE |
|---|---|
| Industry: | Construction & Engineering |
| Sector: | Industrials |
| Current Symbol: | MTZ |
| CUSIP: | 576323 |
| Website: | mastec.com |
Debt
| Debt-to-Equity Ratio: | 0.89 |
|---|---|
| Current Ratio: | 1.33 |
| Quick Ratio: | 1.22 |
Price-to-Earnings
| Trailing P/E Ratio: | 106.18 |
|---|---|
| Forward P/E Ratio: | 26.88 |
MTZ Technical Analysis vs Fundamental Analysis
Buy
75
MasTec, Inc. (MTZ)
is a Buy
Is MasTec, Inc. a Buy or a Sell?
-
MasTec, Inc. stock is rated a BuyThe current MasTec, Inc. [MTZ] share price is $219.12. The Score for MTZ is 75, which is 50% above its historic median score of 50, and infers lower risk than normal.